Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tiziana Life Sciences ( (TLSA) ) has issued an announcement.
On February 25, 2026, Tiziana Life Sciences reported new biomarker data from an open-label expanded-access program of intranasal foralumab in 10 patients with non-active secondary progressive multiple sclerosis with progression independent of relapse activity. Investigators from Brigham and Women’s Hospital presented a late-breaking poster showing that treatment was associated with reduced cerebrospinal fluid inflammatory markers, increased neuroprotective proteins, and decreased microglial activation on [F-18]PBR06-PET imaging, alongside clinical stability or improvement without serious treatment-related adverse events.
The data provide the first demonstrated link between reduced microglial PET signal and favorable CSF proteomic shifts during nasal foralumab therapy in this patient group, reinforcing the biologic plausibility of Tiziana’s approach. These findings strengthen the mechanistic rationale for the company’s ongoing randomized Phase 2a trial in non-active secondary progressive MS and support its strategic positioning around intranasal foralumab as a differentiated, potentially safer immunomodulatory option in progressive neuroinflammatory disease.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on breakthrough immunotherapies delivered via alternative routes such as intranasal administration. Its lead product candidate is intranasal foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical development, targeting neuroinflammatory and neurodegenerative diseases including non-active secondary progressive multiple sclerosis.
Average Trading Volume: 299,186
Technical Sentiment Signal: Hold
Current Market Cap: $159.3M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.